Everything below concerns Cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
== Awards and honours == 2020 Preis der Stadt Wien für Naturwissenschaften 2017 European Research Council (ERC) Advanced Grant 2015 Honorary member of the Swiss Society for Allergology and Immunology 2010 Virchow Medal, Medical Faculty, University of Würzburg 2012 European Research Council (ERC) Advanced Grant 2009 Full member of the Austrian Academy of Sciences 2005 Corresponding member of the Austrian Academy of Sciences 2001 Wittgenstein Award 2000 Member of the Academia Europaea 1990 Member of the European Molecular Biology Organization (EMBO) 1981 Postdoctoral fellowship (Swiss National Science Foundation)
Xylazine is a potent α2-adrenergic receptor agonist. When xylazine and other α2-adrenergic receptor agonists are administered, they distribute throughout the body within 30 to 40 minutes. Due to xylazine's highly lipophilic nature, it directly stimulates central α2-adrenergic receptors as well as peripheral α-adrenergic receptors in a variety of tissues. As an agonist, xylazine reduces release of norepinephrine in the central nervous system. It does so by mimicking norepinephrine in binding to the pre-synaptic surface autoreceptors, which leads to feedback inhibition of norepinephrine release. Recent data suggests that xylazine treatment can induce dopamine release in the nucleus accumbens through an unresolved mechanism, and this effect is blocked by atipamezole. Xylazine also serves as a transport inhibitor by suppressing norepinephrine transport function through competitive inhibition of substrate transport. Accordingly, xylazine significantly increases Km and does not affect Vmax. This likely occurs by direct interaction on an area that overlaps with the antidepressant binding site. For example, xylazine and clonidine suppress uptake of iobenguane (MIBG), a norepinephrine analogue, in neuroblastoma cells. Xylazine's chemical structure closely resembles clonidine. It has also been reported that xylazine activates the κ-opioid receptors, with low potency, which may contribute to its effects. Unlike other α2-adrenergic receptor agonists xylazine does not have any imidazoline receptor activity.
Humans can experience all of the above-mentioned varieties of pair bonds. These bonds can be temporary or last a lifetime. They also engage in social pair bonding, where two form a close relationship that does not involve sex. Like in other vertebrates, pair bonds are created by a combination of social interaction and biological factors including neurotransmitters like oxytocin, vasopressin, and dopamine. Pair bonds are a biological phenomenon and are not equivalent to the human social institution of marriage. Married couples are not necessarily pair bonded. Marriage may be a consequence of pair bonding and vice versa. One of the functions of romantic love is pair bonding.
In the same month, The United Kingdom published its 10-year National AI Strategy, which states the British government "takes the long-term risk of non-aligned Artificial General Intelligence, and the unforeseeable changes that it would mean for ... the world, seriously". The strategy describes actions to assess long-term AI risks, including catastrophic risks. The British government held first major global summit on AI safety. This took place on the 1st and 2 November 2023 and was described as "an opportunity for policymakers and world leaders to consider the immediate and future risks of AI and how these risks can be mitigated via a globally coordinated approach". China Media Project stated "key aspects of its approach remain fundamentally unsafe by the standards of democratic societies worldwide", arguing that part of China's AI safety approach is focused on strengthening the Chinese Communist Party (CCP)'s information control. Government organizations, particularly in the United States, have also encouraged the development of technical AI safety research. The Intelligence Advanced Research Projects Activity initiated the TrojAI project to identify and protect against Trojan attacks on AI systems. The DARPA engages in research on explainable artificial intelligence and improving robustness against adversarial attacks. And the National Science Foundation supports the Center for Trustworthy Machine Learning, and is providing millions of dollars in funding for empirical AI safety research.
Procedural aspects in pronouncing death also contribute to delay, so the condemned is usually pronounced dead within 10–20 minutes of starting the drugs. Supporters of the death penalty say that a huge dose of thiopental, which is between 14 and 20 times the anesthetic-induction dose and which has the potential to induce a medical coma lasting 60 hours, could never wear off in only 10–20 minutes.
Sources: en.wikipedia.org
=== Clipping === The clipping method is similar to the capping reaction except that in this case the dumbbell shaped molecule is complete and is bound to a partial macrocycle. The partial macrocycle then undergoes a ring closing reaction around the dumbbell-shaped molecule, forming the rotaxane.
== History == JRT was developed by Jeremy R. Tuck (J.R.T.), Lee E. Dunlap, David E. Olson, and other colleagues at Delix Therapeutics and the University of California, Davis. It was first described in the scientific literature by 2022 and was subsequently described in greater detail in 2025.
"You have no idea what the Tour de France is," Henri said. "It's a Calvary. Worse than that, because the road to the Cross has only 14 stations and ours has 15. We suffer from the start to the end. You want to know how we keep going? Here..." He pulled a phial from his bag. "That's cocaine, for our eyes. This is chloroform, for our gums." "This," Ville said, emptying his shoulder bag "is liniment to put warmth back into our knees." "And pills. Do you want to see pills? Have a look, here are the pills." Each pulled out three boxes. "The truth is," Francis said, "that we keep going on dynamite." Henri spoke of being as white as shrouds once the dirt of the day had been washed off, then of their bodies being drained by diarrhea, before continuing:
On September 25, Xi and Peng returned to the White House with Donald and Melania Trump. They then attended a tea ceremony in the Red Room. Trump said US farmers "are going to be very happy" with the talks, adding "A lot of very positive things happened, but America is very happy about this visit and I’m sure China is very happy also". He said "We’ve had a tremendous visit from two spectacular people" and "We’ve really enjoyed it and I think we’ve been tremendous strides. We’ve made great strides, very positive for both countries." During this tea ceremony, Xi said that he and Trump "are like two people who are charting the course for the great ship of China-U.S. relations." Xi also confirmed that two leaders will to see each other later this year in twice, including APEC summit in Shenzhen and G20 Summit in Miami. Later, Xi and Trump visited the National Archives, and viewed the Declaration of Independence, the Constitution and the Bill of Rights. According to the NPR, a table that included a temporary display showcasing a brick from the Great Wall of China and an 19th century scroll sent by a Qing emperor was removed because the display also planned to show the Treaty of San Francisco, which China considers as illegitimate because it was not a signatory. Other documents, including Six Assurances and the Three Communiqués, were also discussed for display, but ultimately not included.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.